Omid Hamid MD
Chief of Research and Immunotherapy • ImmunoOncology • Phase I Clinical Trials • Melanoma • Cutaneous Oncology
Last synced from Twitter 16m ago
Dr. Whitman on Expanding the Benefit of Immunotherapy in Solid Tumors
Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.
Living With Melanoma Symposium co-hosted with The Angeles Clinic & Research Institute
AIM’s Living With Melanoma Symposiums bring together leading medical and wellness professionals with people affected by melanoma to learn, connect, and share...
Omid Hamid MD
Treating #melanoma is a team event. Grateful for our #volunteers @BMS_ImmunOnc_US team @angelesclinic @AIMatMelanoma youtu.be/fEEqOJkOpiQ pic.twitter.com/klzAlZmYH1
41h
(Overview) Melanoma: Clues to Improved Therapeutic Efficacy from Disease Pathogenesis
David E. Fisher, MD, PhD, Massachusetts General Hospital, Boston, Massachusetts This presentation explores features of cutaneous adaptation to sun/UV that su...
Omid Hamid MD
2018 Chabner Colloquium and STO Annual Meeting @MGHMedicine David Fischer discusses epitope spreading and other mechanisms for melanoma therapy
4d
UPMC Hillman Cancer Center Names New Leader of Cancer Immunotherapy
Medical oncologist and clinical investigator, Dr. Jason Luke to direct UPMC Hillman Immunotherapeutics Center.
Title not found
Omid Hamid MD
#ASCO18 abstracts just released. Can't wait to read and enjoy! @angelesclinic
@ASCO
4d
Blocking BRAF ubiquitination may be an effective treatment approach in melanoma
The protein BRAF is a key player in the development of many different types of cancer, including melanoma.
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
The great debate session at the 2018 Melanoma Bridge congress (November 29–December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint...
Eligibility for and Response to Checkpoint Inhibitor Immunotherapy Drugs for Cancer
This cross-sectional study estimates the percentage of US patients with cancer who were eligible for and who responded to checkpoint inhibitor immunotherapy drugs between 2011 and 2018.
ASCO Announces Top Studies to Be Presented at 2019 Annual Meeting
ALEXANDRIA, Va. – Cancer experts from around the world will gather to share the latest clinical cancer research impacting patient care at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO). Advances in targeted therapies for...
1
Omid Hamid MD
@ASCO Plenary announced
Can't wait
asco.org/about-asco/pre…
#ASCO2019 @angelesclinic
24d
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
AbstractBackground. PD-1 blocking monoclonal antibodies improve the overall survival of patients with advanced melanoma but the optimal duration of treatment h
Omid Hamid MD
#When to discontinue PD-1 Therapy for melanoma ?
real world experience from @ProfGLongMIA
and experts.
27d
Expo Register | OncLive - Bringing the Oncology Community Together
OncLive your connection to everything oncology, interviews and videos from thought leaders and cutting edge articles and resources.
Register — International Cancer Immunotherapy Conference
Register for CICON19, September 25 – 28, 2019, Espace de la Defense, Paris, France.
Personalizing Cancer Treatment
Dr. Patrick Hwu discusses the current state of cancer care and how recent advances are enabling doctors to tailor their strategies to fit individual patients.
Omid Hamid MD
Thanks @CancerResearch for the best intro to #Immunotherapy for physician colleagues and our patients @angelesclinic with Dr. Patrick Hwu from @MDAndersonNews
33d
First U.S. Patients Treated With CRISPR As Gene-Editing Human Trials Get Underway
This could be a crucial year for the powerful gene-editing technique CRISPR as researchers start testing it in patients to treat diseases such as cancer, blindness, and sickle cell disease.
Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 2, 2019--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that new preclinical data supporting the development of microbiome therapeutics for immuno-oncology (poster title “Leveraging gut microbiota...
From Bench to Bedside: Dr. Padmanee Sharma Talks Biomarkers, Broken Arms and Being the Nobelle of the Ball
A Q&A with One of Cancer Immunotherapy’s Leading Minds When she was 7 years old, Padmanee “Pam” Sharma ended up in the hospital in a coma with a broken arm. Though she didn’t know it at the time, that fateful trauma would in part lead her down the...